Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01189 (
beta-endorphin
)
21,003
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
1. The antinociceptive effect of compound 48/80 was reversed by the pretreatment with an angiotensin-converting enzyme (ACE) inhibitor,
Hoe
498, in a dose-dependent manner and with a opiate receptor antagonist, naloxone (5.0 mg/kg, s.c.) in rats. 2. The increase of plasma
beta-endorphin
-like immunoreactivity produced through s.c. administration of compound 48/80 was attenuated by the pretreatment with
Hoe
498 but not with naloxone. 3. The present data suggest the possible involvement of renin-angiotensin system in compound 48/80-induced analgesia in rats.
...
PMID:The role of renin-angiotensin system in compound 48/80-induced analgesia in rats. 252 74
In order to investigate influences of
corticotropin
-releasing hormone (CRH) and
corticotropin
fragment (adrenocorticotropic hormone, ACTH, 4-9) on auditory perception processes, 10 subjects received either a placebo (sodium chloride 0.9%), CRH (100 micrograms) or ACTH 4-9 (
Hoe
427, 300 micrograms) intravenously on different days. Late auditory evoked potentials (AEP) were computed and further analyzed using the brain electric source analysis method. As expected, CRH administration was followed by a rise in plasma cortisol and ACTH concentrations, whereas the injection of the ACTH 4-9 fragment did not alter plasma cortisol concentrations. In contrast to these different hormonal responses, both CRH and ACTH 4-9 modulated AEP in a similar manner, differing in quantity rather than in quality. The changes in AEP after the administration of ACTH 4-9 were most likely induced by a direct CNS action, whereas for the CRH effects, an indirect mechanism throughout the release of endogenous ACTH must be considered.
...
PMID:Changes in late auditory evoked potentials induced by corticotropin-releasing hormone and corticotropin fragment 4-9 in male controls. 892 35